Adis Journals Overview

Transcription

1 Adis Journals Overview

2 Introduction Adis Rapid Publishing Service Life after publication AdisOnline.com The Adis publishing heritage The Adis Journals brand has evolved over 40 years to become synonymous with current, comprehensive and objective journal publishing, with a strong specialism in pharmacology and pharmacotherapy. Adis has proved that acute customer focus can be achieved without compromising the highest ethical publishing standards, including rigorous independent peer review. Adis Journals endorses the ICMJE guidelines and is a member of COPE, observing their Code of Conduct and Best Practice Guidelines for Journal Editors. Publishing research at every stage of the drug lifecycle Covering all aspects of the drug development continuum from bench to bedside, Adis Journals are a unique must-have resource for researchers, clinicians, clinical pharmacists, clinical pharmacologists, teachers, students, and anyone with an interest in drug therapy and pharmacology. The Adis portfolio offers a wide range of specialist titles publishing a complementary blend of original research, independent Adis Drug Evaluations and invited reviews. Adis Editors possess great insight into the trends within their speciality areas, and are committed to recognizing and meeting the needs of their readership. Most Adis journals are indexed in MEDLINE and have an international following of paid subscribers. Key features The following elements of the Adis Journals program have been refined over 4 decades: Strong customer service ethic Adis publishing team takes great pride in the speed and quality of the customer service they provide. With offices in every major market around the world, there is always a local Adis representative available to provide a local language service. Cascading peer review If a submitted article is rejected by an Adis journal Editor based on peer-review comments, those comments can be passed on to the Editor of another relevant Adis journal and further peer review may not be necessary. Adis Open Access 9 An option to publish any submitted original research article under an open access license 9 Available for any Adis journal that publishes original research articles 9 Articles are peer reviewed and must meet the journal s usual acceptance criteria 9 Journal Editors are blinded to the open access status of papers so that there is no influence on editorial decisions 9 Authors pay an Article Processing Charge (APC) of US$3,000 upon acceptance 9 Open access articles are then published online-only, and are freely available on AdisOnline.com and Ovid to read, copy, share and distribute for non-commercial purposes 9 An optional service for any submitted original research article working days peer review guaranteed 9 Publish in a choice of well-established journals in as little as 3-4 weeks 9 Rigorous assessment by Editors and external peer reviewers 9 Small fee to cover fast-track administration costs Adis Drug Evaluations & Drug Profiles 9 Comprehensive single-agent reviews, highlighting the unique clinical benefits of a drug 9 Independently researched and expertly written by skilled Adis writers 9 Peer reviewed externally by therapy area experts 9 Written to country-specific labelling where appropriate 9 Timed to maximize clinical relevance and topicality for the healthcare community 9 Remind healthcare professionals of the wealth of best evidence supporting a product s place in therapy 9 Articles published in Adis journals appear on AdisOnline.com, a modern well-established journal platform with high volumes of traffic 9 Adis articles are also distributed on Ovid and through many other aggregation and document delivery platforms 9 AdisOnline is optimized for a perfect viewing experience on most mobile devices 9 Articles on AdisOnline are available: - In HTML and PDF versions - In EPUB version for e-reader devices such as ipad - With a facility to export tables and figures to PowerPoint - With hyperlinks to referenced articles - In URL formats that are easily located by search engines and library systems - With a facility to attach Supplementary Digital Content to the article which could be as simple as an appendix of data tables, or as complex as a video or podcast (e.g. author commentary) Article usage reports These reports are available on request after an article is published on AdisOnline. They use WebTrends data to show the number of times an article has been viewed since publication. They also provide a ranking of those article views versus all the other articles viewed in that journal during the same period. Digital eprints Adis uses the latest digital book technology and digital rights management, providing flexible eprint solutions with ROI metrics to meet a wide range of communication objectives.

3 Therapy area strengths General Medicine Health Outcomes Cardiology, CNS, and Dermatology A strong presence in selected therapy areas Drugs Premier journal, publishing pivotal phase 3 research and seminal reviews PharmacoEconomics Premier health economics journal CDI Ideal vehicle for supporting studies Applied Health Economics and Health Policy Sister journal to PharmacoEconomics with a broader scope Drugs in R&D A fully open access journal for supporting research and reviews The Patient: Publishes studies of patient preferences and patient-centered outcomes Special Disciplines Industry-leading titles in key areas of drug development Special Patient Populations Pediatric Drugs Rapid journal publication is becoming increasingly important with European requirements to post pediatric study results in EudraCT database within 6 months of completion Drugs & Aging Increasingly important area as older population grows

4 Best publishing practice Adis Journals is committed to the best ethical publishing practices, endorsing the Uniform Requirements for Manuscripts Submitted to Biomedical Journals developed by the International Committee for Medical Journal Editors (ICMJE), and is also a member of the Committee on Publication Ethics (COPE), observing their Code of Conduct and Best Practice Guidelines for Journal Editors. Copyright Unless their article is published under an open access license, authors will be asked to sign a transfer of copyright agreement, which recognizes the common interest that both the journal and author(s) have in the protection of copyright. Authorship criteria Each author should have participated sufficiently in the submitted work to take public responsibility for appropriate portions of the content. Authors should meet all the following criteria: The corresponding author takes responsibility for the work as a whole, from inception to the published manuscript, and will be responsible for sign-off of the final proofs prior to publication. The corresponding author must provide a statement indicating the names and contributions of all persons who have provided input to the manuscript, but who do not fulfil authorship criteria. This information will be published in an Acknowledgments section of the paper. Authors should obtain written permission from individuals to be named in the Acknowledgments section. Conflict of Interest Statement for authors and role of the funding source To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. Both conflicts and the role of any funding source must be summarized in the Acknowledgments section of the paper. Ethical conduct of research For human or animal experimental investigations, appropriate institutional review board approval is required, and/or the principles Declaration of Helsinki should be followed. Protection of patients rights to privacy Identifying information should not be included in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient gives written informed consent for publication. Permissions required to reproduce or adapt material Authors must acknowledge and seek the appropriate permissions to use all text, illustrations, and tables adapted or reproduced from other publications. Duplicate publication and duplicate submission Manuscripts are considered with the understanding that they have not been published previously and are not under consideration by another publication. Clinical trial registration With the exception of Clinical Drug Investigation all Adis journals require, as a condition of consideration of original clinical research for publication, prospective registration of clinical trials in a public trials registry before recruitment of any participants. This applies to trials which commenced after 1 July 2005: for older trials retrospective registration will be acceptable, but only if completed before submission of the manuscript to the journal. The full Adis policies for each journal are available for review on AdisOnline. The key requirements for authors are as follows: 9 Conceived and planned the work that led to the manuscript, and/or played an important role in the acquisition, analysis, and interpretation of the data 9 Wrote the paper and/or made substantive suggestions for revision 9 Approved the final submitted version Use of personal communications and unpublished data Authors must include a signed statement of permission from each individual identified as a source of information in a personal communication or as a source for unpublished data.

5 Contact us To view Adis journals online go to: For more information please contact your local representative, or alternatively: Europe and Rest of World Jan Seal-Roberts Tel: USA North America and East Coast Garrett R. Groesbeck Tel: North America, Midwest and West Coast Philip E. Thoman Tel: